Targeting ACKR3/CXCR7 enhances platelet anticoagulant acylcarnitines and modulates procoagulant function.

Targeting CXCR7 increases anticoagulant long-chain acylcarnitines in platelets and reduces thrombotic activity, offering a potential therapeutic approach for thrombosis.

• Why it matters: Thrombosis and hypercoagulation are major contributors to cardiovascular diseases, yet strategies to modulate platelet procoagulant functions and lipid oxidation are limited, necessitating new targets.
• What they did: The study used pharmacological CXCR7 agonists to examine effects on platelet mitochondrial function, lipid oxidation, and procoagulant activity, measuring lipid levels, mitochondrial respiration, and thrombotic responses in human and murine models.
• The result: Activation of CXCR7 enhanced anticoagulant lipid production, improved mitochondrial metabolism, and decreased thrombus formation, suggesting that CXCR7 targeting can mitigate thrombotic risk and restore anticoagulant lipid balance in cardiovascular conditions.